Evidence map›Paper›PMID 40330817›Full record

ArticleDrug design, development and therapy2025

Optimized Sampling Strategies for Isoniazid in East Asian Pediatric Populations Using Population Pharmacokinetics-Informed Approaches.

Gehang Ju, Xin Liu, Yeheng Peng, Wenyu Yang, Nuo Xu, Qingfeng He, Chenchen Zhang, Lulu Chen, Nan Yang, Gufen Zhang and 4 more

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gehang JuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.ORCID 0000-0002-0721-5296
Xin LiuDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.ORCID 0009-0009-5595-3195
Yeheng PengDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Wenyu YangDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.ORCID 0000-0002-9057-4520
Nuo XuDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.ORCID 0009-0003-7815-1124
Qingfeng HeDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.ORCID 0000-0001-5795-1550
Chenchen ZhangSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Lulu ChenHunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, People's Republic of China.
Nan YangHunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, People's Republic of China.
Gufen ZhangHunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, People's Republic of China.
Chao LiHunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, People's Republic of China.
Pan SuHunan Chest Hospital, Changsha, People's Republic of China.
Xiao ZhuDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Dongsheng OuyangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.ORCID 0000-0002-1743-8610

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Isoniazid exposure in vivo is significantly affected by NAT2 genotypes and has ethnic differences. To optimize the sampling strategy for isoniazid in East Asian pediatric populations. We employed a model-informed optimization approach based on INH population pharmacokinetic (PopPK) models. Methods: We selected PopPK models for children and East Asian adults and optimized the sampling strategy using PopED (Population Experimental Design), a method that helps identify the most efficient sampling points for maximizing parameter estimation accuracy. Virtual patients with varying NAT2 phenotypes were created, and real-world pediatric scenarios were evaluated using questionnaire data, sampling windows, and stochastic simulations. Results: From eight analyzed models (four for East Asian adults and four for non-East Asian pediatrics), we simplified two over-parameterized models using lumping without loss of performance. The optimized clinical sampling strategy involved collecting samples at 0.25 [0-0.5], 1.5 [1-2], 6 [3-8], 12 [9-14], and 24 [22-24] hours post-dose. Simulation verification showed that re-estimated major PK parameters had acceptable relative biases and relative standard error (<30%). Conclusion: Traditional adult sampling strategies are inadequate for East Asian pediatric populations. A tailored strategy involving up to five samples can accurately estimate INH PopPK parameters and should be considered for clinical implementation to optimize treatment and reduce patient sampling burden.

Indexed as

Antitubercular AgentsEast Asian PeopleIsoniazidModels, BiologicalAdolescentAdultArylamine N-AcetyltransferaseChildChild, PreschoolComputer SimulationHumansMaleAntitubercular AgentsArylamine N-AcetyltransferaseIsoniazidNAT2 protein, humanisoniazidoptimal sampling designpopulation pharmacokineticsstochastic simulation and estimation

Identifiers

PMID40330817
PMCPMC12051976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.